immuno oncology frontiers world miami


Keith Knutson

Dr Keith Knutson

Director, Cancer Vaccine & Immune Therapies Program, Mayo Clinic

Dr. Keith L. Knutson is currently Professor in the Department of Immunology at Mayo Clinic in Jacksonville and Director, Mayo Clinic Florida Cancer Research Program.  He received his Ph.D. from the University of Georgia in Physiology and Pharmacology in 1995 and completed two post-doctoral fellowships in immunology, one at the University of British Columbia and the other at the University of Washington. He was a 2004 recipient of a Howard Temin Award from the National Cancer Institute.  Dr. Knutson’s current interests and research focuses on the immunology and immunotherapy of breast and ovarian cancers.  Interests are in both the basic immunobiology and clinical translation, including clinical trials.  The laboratory conducts research on cancer vaccines focuses on augmenting T cell immunity using peptide and virus-based vaccines.  These vaccine strategies are primarily aimed at preventing the patients from relapsing after optimal conventional therapies.   Dr. Knutson is currently (1) a member of the Tumor Microenvironment Study Section at the Center for Scientific Review at the National Institutes of Health, (2) a member of the Integration Panel of Department of Defense’s Ovarian Cancer Research Program, and (3) a Susan G. Komen Scholar.


  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy